Beam Therapeutics Inc. (BEAM) stock
BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3014% below fair value
$20.65−0.29 (-1.38%)
Close on Nov 17, 2026Market cap $2.13BP/E –Yield –
Beam Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Beam Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$378.02M. For fiscal 2025 it was -$383.69M. The highest annual figure on record is -$75.15M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$383.69M | – |
| FY2024 | Dec 31, 2024 | -$415.57M | – |
| FY2023 | Dec 31, 2023 | -$176.49M | – |
| FY2022 | Dec 31, 2022 | -$338.48M | – |
| FY2021 | Dec 31, 2021 | -$392.47M | – |
| FY2020 | Dec 31, 2020 | -$132.76M | – |
| FY2019 | Dec 31, 2019 | -$75.15M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$126.55M | – |
| Q1 FY2026 | Mar 31, 2026 | -$107.22M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.45M | – |
| Q3 FY2025 | Sep 30, 2025 | -$126.81M | – |
| Q2 FY2025 | Jun 30, 2025 | -$120.15M | – |
| Q1 FY2025 | Mar 31, 2025 | -$119.29M | – |
| Q4 FY2024 | Dec 31, 2024 | -$100.04M | -175.3% |
| Q3 FY2024 | Sep 30, 2024 | -$106.50M | – |
| Q2 FY2024 | Jun 30, 2024 | -$104.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$104.13M | – |
| Q4 FY2023 | Dec 31, 2023 | $132.86M | – |
| Q3 FY2023 | Sep 30, 2023 | -$108.27M | – |
| Q2 FY2023 | Jun 30, 2023 | -$102.15M | – |
| Q1 FY2023 | Mar 31, 2023 | -$98.93M | – |
| Q4 FY2022 | Dec 31, 2022 | -$88.99M | – |
| Q3 FY2022 | Sep 30, 2022 | -$91.30M | – |
| Q2 FY2022 | Jun 30, 2022 | -$81.97M | – |
| Q1 FY2022 | Mar 31, 2022 | -$76.23M | – |
| Q4 FY2021 | Dec 31, 2021 | -$63.48M | – |
| Q3 FY2021 | Sep 30, 2021 | -$69.63M | – |
| Q2 FY2021 | Jun 30, 2021 | -$58.97M | – |
| Q1 FY2021 | Mar 31, 2021 | -$200.37M | – |
| Q4 FY2020 | Dec 31, 2020 | -$40.80M | – |
| Q3 FY2020 | Sep 30, 2020 | -$37.32M | – |
| Q2 FY2020 | Jun 30, 2020 | -$26.29M | – |
| Q1 FY2020 | Mar 31, 2020 | -$28.36M | – |
| Q4 FY2019 | Dec 31, 2019 | -$26.37M | – |
| Q3 FY2019 | Sep 30, 2019 | -$18.02M | – |
| Q2 FY2019 | Jun 30, 2019 | -$17.65M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.11M | – |
See a number that looks wrong?